相关实验视频
Updated: May 2, 2026

10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.3K
在宫癌患者中适应性放射疗法 (SWIFT-1):多中心,开放标签,双臂,第三阶段,随机对照研究的研究方案
Zheng Zeng1, Yining Chen2, Jie Qiu1
1Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, NO.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China.
Radiation oncology (London, England)
|July 16, 2025
概括
这项试验将中度低分离放射治疗 (MHRT) 与局部晚期宫癌的常规分离放射治疗 (CFRT) 进行比较. 它将确定MHRT是否是一种安全有效的CFRT替代方案,可能减少治疗负担.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 临床试验 临床试验
背景情况:
- 外部光束放射治疗 (EBRT) 是局部晚期子宫癌的标准.
- 适度低分离放射治疗 (MHRT) 可能会减少治疗负担,但需要更多的证据.
- 由于缺乏现代技术,现有研究可能会高估MHRT的毒性.
研究的目的:
- 评估适度低分离的在线自适应性放射治疗 (oART) 与常规分离放射治疗 (CFRT) 的非劣势.
- 评估MHRT的疗效和安全性,作为CFRT在宫癌治疗中的替代方案.
- 研究oART在局部晚期宫癌管理中的潜力.
主要方法:
- 未来的,多中心的,随机对照的,非劣势的第三期试验.
- 440名参与者被随机分配1:1接受MHRT或CFRT,两者同时接受化疗和放射治疗.
- 主要终点:无进展的3年生存期;次要终点包括毒性和生活质量.
主要成果:
- 这部分将在研究完成后填写.
结论:
- 这项试验将从前性地评估MHRT在有效性和安全性方面与CFRT的非劣势性.
- 它将评估中度低分离的oART作为局部晚期宫癌的可行替代方案.
- 结果将为临床实践提供关于宫癌中低分离放射治疗的信息.
相关概念视频
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K

